Lack of p16/CDKN2 alterations in thyroid carcinomas

Cancer Letters

Volumn 101, Issue 1, 1996, Pages 85-92

  Yane, Katsunari ^a   Konishi, Noboru ^a   Kitahori, Yoshiteru ^a   Naito, Hiroaki ^a   Okaichi, Kunio ^a,b   Ohnishi, Takeo ^a   Miyahara, Hiroshi ^a   Matsunaga, Takashi ^a   Hiasa, Yoshio ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Human thyroid neoplasms; p16 CDKN2; p53; Single strand conformation polymorphism

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GENETICS; CARCINOMA CELL; CLINICAL ARTICLE; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; UNDIFFERENTIATED CARCINOMA;

EID: 0030046482     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04117-1     Document Type: Article

References (30)

1. Cairns, P., Mao, L., Merlo, A., Lee, D.J., Schwab, D., Eby, Y., Tokino, K., Riet, P., Blaugrund, J.E. and Sidransky, D. (1994) Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-417.
2. Caldas, C., Hahn, S.A., da Costa, L.T., Redston, M.S., Schutte, M., Seymour, A.B., Weinstein, C.L., Hruban, R.H., Yeo, C.J. and Kern, S.E (1994) Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nature Genet., 8, 27-32.
3. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G. and Pierotti, M.A. (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91, 1753-1760.
4. Fagin, J.A., Matsuo, K., Karmakar, A., Chen, D.L., Tang, S.H. and Koeffler, H.P. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 91, 179-184.
5. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature, 371, 257-261.
6. Harper, J.W., Adami, G.R., Wel, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
7. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
8. Hussussian, C.J., Struewing, J.P., Goldstein, A.M., Higgins, P.A.T., Ally, D.S., Sheahan, M.D., Clark, W.H., Tucker, M.A. and Dracopoli. N.C. (1994) Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
9. Ito, T., Seyama, T., Hayashi, Y., Hayashi, T., Dohi, K., Mizuno, T., Iwamoto, K., Tsuyama, N., Nakamura, N. and Akiyama, M. (1994) Establishment of two human thyroid carcinoma cell lines (8305C, 8505C) bearing p53 gene mutations. Int. J. Oncol., 4, 583-586.
10. Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T., Hayashi, Y., Dohi, K., Nakamura, N. and Akiyama, M. (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res., 52, 1369-1371.
11. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day. RS., Johnson, B.E. and Skolnick, M.H. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
12. Lemoine, N.R., Mayall, E.S., Wyllie, F.S., Williams, E.D., Goyns, M., Stringer, B. and Wynford-Thomas, D. (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene, 4, 159-164.
13. Lehman, T.A., Bennetto, W.P., Metcalf, R.A., Welsh, J.A., Ecker, J., Modali, R.V., Ullrich, S., Romano, J.W., Appella, E., Testa, J.R., Gerwin, B.I .and Harris, C.C. (1991) p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51, 4090-4096.
14. Levine, A.J., Momand, J. and Finlay, C.A (1991) The p53 tumour suppressor gene. Nature, 351, 453-456.
15. Mazars, R., Pujol, P., Maudelonde, T., Jeanteur, P. and Theillet, C. (1991) p53 mutations in ovarian cancer: a late event? Oncogene, 6, 1685-1690.
16. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y. (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor / cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397.
17. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Moduli, R., Harris, C.C. and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705-708.
18. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K. and Carson, D.A. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
19. INK4B/MTS2. and p18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448-1451.
20. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. and Sekiya, T. (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proc. Natl. Acad. Sci. USA, 86, 2766-2770.
21. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
22. Santoro, M., Carlomagno, F., Hay, I.D., Herrmann, M.A., Grieco, M., Melillo, R., Pierotti, M.A., Bongarzone, I., Della Porta, G., Berger, N., Peix, J.L., Paulin, C., Fabien, N., Vecchio, G., Jenkins, R.B. and Fusco, A. (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest., 89, 1517-1522.
23. Schmidt, E.E., Ichimura, K., Reifenberger, G. and Collins, V.P. (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54, 6321-6324.
24. INK4, the product of the putative tumor suppressor gene MTS1. Oncogene, 9, 3475-3482.
25. Serrano, M., Hannon, G.J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707.
26. Shi, Y, Zou, M., Schmidt, H., Juhasz, F., Stensky, V., Robb, D. and Farid, N.R. (1991) High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res., 51, 2690-2693.
27. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M.L., Cavenee, W. and Vogelstein, B. (1992) Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature, 355, 846-847.
28. Spruck, C.H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A.R., Lin, M.F., Gonzales, F., Tsai, Y.C. and Jones, P.A. (1994) p16 gene in uncultured tumors. Nature, 370, 183-184.
29. Stranks, G., Height, S.E., Mitchell, P., Jadayel, D., Yuille, M.A.R., DeLord, C., Clutterbuck, R.D., Treleaven, J.G., Powles, R.L., Nacheva, E., Oscier, D.G., Karpas, A., Lenoir, G.M., Smith, S.D., Millar, J.L., Catovsky, D. and Dyer, M.J.S. (1995) Deletions and rearrangements of CDKN2 in lymphoid malignancy. Blood, 85, 893-901.
30. Zhang, S.Y., Klein -Szanto, A.J.P., Sauter, E.R., Shafarenko, M., Mitsunaga, S., Nobori, T., Carson, D.A., Ridge, J.A. and Goodrow, T.L. (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053.